Validating 7-items Overactive Bladder Symptom Score (OABSS) through Arabic linguistic version

Fadi Sawaqed, Mohammed Suoub, Fadi Sawaqed, Mohammed Suoub

Abstract

The scoring of the 7-item Overactive Bladder Symptom Score (OABSS) questionnaire is unusual because its scale varies with the same maximum and minimum scoring values and quantifies all aspects of OAB. The questionnaire also contains a graded response for urgency. The current study is mainly concerned with the development and validation of the OABSS questionnaire for Jordanian patients. The process of translating the English OABSS questionnaire into the Arabic language involved forward and backward translations. Afterward, a prospective study was conducted to validate the Arabic version of the OABSS questionnaire by examining 235 patients from the outpatient clinics of Karak Governorate Teaching Hospital. The Arabic OABSS questionnaire was completed by all the enrolled patients before and after three months of treatment with solifenacin 5 mg taken once daily. The study included 235 regular patients (152 females and 83 males) diagnosed with OAB in accordance with the definition of the International Continence Society (ICS). The results showed major and significant differences on all seven domains of the questions on the OABSS questionnaire before and after receiving treatment (p < 0.05). Confirmatory Factor Analysis was used to measure the reliability and the questionnaire was found to be highly reliable for the construct variables. The findings derived from the current study would be beneficial for local urologists and researchers, as the Arabic version of the OABSS questionnaire was proven to be a reliable instrument for use in the assessment of OAB. Future studies are needed to compare different translated questionnaires relating to OAB.Trial registration number: NCT04309890.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Factor analysis.

References

    1. Oonnell KA, Singer J, Rajan S. Stimulus-associated urinary urges in overactive bladder syndrome. Neurourol. Urodyn. 2018;37:284–290. doi: 10.1002/nau.23290.
    1. Chun JY, Song M, Han JY, Na S, Hong B, Choo MS. Clinical factors associated with dose escalation of solifenacin for the treatment of overactive bladder in real-life practice. Int. Neurourol. J. 2014;18:23. doi: 10.5213/inj.2014.18.1.23.
    1. Melotti IG, Juliato CR, de Albuquerque Coelho SC, Lima M, Riccetto CL. Is there any difference between depression and anxiety in overactive bladder according to sex? A systematic review and meta-analysis. Int. Neurourol. J. 2017;21:204. doi: 10.5213/inj.1734890.445.
    1. Xu D, Zhao M, Huang L, Wang K. Overactive bladder symptom severity, bother, help-seeking behavior, and quality of life in patients with type 2 diabetes: a path analysis. Health Qual. Life Outcomes. 2018;16:1. doi: 10.1186/s12955-017-0829-z.
    1. Gotoh M, Kobayashi T, Sogabe K. Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder. Neurourol. Urodyn. 2015;34:730–735. doi: 10.1002/nau.22663.
    1. Elbaset MA, Hashem A, Taha DE, Zahran MH, El-Hefnawy AS. Validation of the Arabic linguistic version of the overactive bladder symptoms score questionnaire. Arab. J. Urol. 2019;1:5. doi: 10.1080/2090598x.2019.1627061.
    1. Lozano-Ortega G, Gooch K, Walker D, Rogula B, Deighton A, Johnston KM, Dmochowski R. The efficacy and safety of mirabegron relative to onabotulinumtoxina in patients with overactive bladder not appropriately managed with an antimuscarinic: a network meta-analysis. Value Health. 2018;21:S266. doi: 10.1016/j.jval.2018.04.1796.
    1. Nobrega R, Greenwell TJ, Pickard R, Ockrim JL, Harding CK. Sacral nerve stimulation versus intravesical botulinum toxin injections for medically refractory overactive bladder: a contemporary review of UK treatment from both clinician and patients’ perspectives. J. Clin. Urol. 2018;11:339–344. doi: 10.1177/2051415817742565.
    1. Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2010;75:491–500. doi: 10.1016/j.urology.2009.07.1325(2010).
    1. Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int. J. Clin. Pract. 2010;64:1287–1293. doi: 10.1111/j.1742-1241.2010.02442.x.
    1. Robinson D, Cardozo L. Antimuscarinic drugs to treat overactive bladder. BMJ. 2012;344:e2130. doi: 10.1136/bmj.e2130.
    1. Ivchenko A, Bödeker RH, Neumeister C, Wiedemann A. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study. BMC Urol. 2018;18:80. doi: 10.1186/s12894-018-0394-8.
    1. Ahmad SM, Aznal SS, Tham SW. Prevalence of overactive bladder syndrome (OABS) among women with gynaecological problems and its risk factors in a tertiary hospital, Negeri Sembilan, Malaysia: implication for primary healthcare providers. Malays. Fam. Phys. 2015;10:2.
    1. Chartier-Kastler E, Rovner E, Hepp Z, Khalaf K, Ni Q, Chancellor M. Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity. Neurourol. Urodyn. 2016;35:595–600. doi: 10.1002/nau.22757.
    1. Kelleher C, Chapple C, Johnson N, Payne C, Homma Y, Hakimi Z, Siddiqui E, Evans C, Egan S, Kopp Z. Development of an overactive bladder assessment tool (BAT): a potential improvement to the standard bladder diary. Neurourol. Urodyn. 2018;37:1701–1710. doi: 10.1002/nau.23479.
    1. Hakimi S, Hajebrahimi S, Mohammadi M, Aminian E, Ghana S. Translation and psychometric properties of Iranian version of overactive bladder syndrome score (Oabss) BMJ Open. 2017;7:2016-015415.207. doi: 10.1136/bmjopen-2016-015415.207.
    1. Blaivas JG, Panagopoulos G, Weiss JP, Somaroo C. Validation of the overactive bladder symptom score. J. Urol. 2007;178:543–547. doi: 10.1016/j.juro.2007.03.133.
    1. Shim JS, Kim JH, Choi H, Park JY, Bae JH. Diagnostic tool for assessing overactive bladder symptoms: could the international prostate symptom storage subscore replace the overactive bladder symptom score? Int. Neurourol. J. 2016;20:209. doi: 10.5213/inj.1632534.267.
    1. Cameron AP, Lewicky-Gaupp C, Smith AR, Helfand BT, Gore JL, Clemens JQ, Yang CC, Siddiqui NY, Lai HH, Griffith JW, Andreev VP. Baseline lower urinary tract symptoms in patients enrolled in the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN): a prospective, observational cohort study. J. Urol. 2018;199:1023. doi: 10.1016/j.juro.2017.10.035.
    1. Wu P, Chen Y, Zhao J, Zhang G, Chen J, Wang J, Zhang H. Urinary microbiome and psychological factors in women with overactive bladder. Front. Cell Infect. Microbiol. 2017;7:488. doi: 10.3389/fcimb.2017.00488.
    1. Guzmán SA, Cuenca EM, García RM, García MB, Rejas J, Broseta-Rico E. Cultural adaptation to Spanish (Spain) of the “overactive bladder-family impact measure (OAB-FIM)” questionnaire. Actas Urol. Esp. (Engl. Ed.) 2017;41:324–332. doi: 10.1016/j.acuroe.2017.04.005.
    1. Park J, Shin DW, You C, Chung KJ, Han DH, Joshi HB, Park HK. Cross-cultural application of the Korean version of Ureteral Stent Symptoms Questionnaire. J. Endourol. 2012;26:1518–1522. doi: 10.1089/end.2012.0235.
    1. Sanguedolce F, Millán-Rodriguez F, Santillana-Altimira JM, Fantova-Alonso A, Sánchez-Martín FM, Angerri-Feu O, Martinez JM, Keeley FX, Joshi HB, Villavicencio-Mávrich H. The Spanish linguistic validation of the ureteral stent symptom questionnaire. J. Endourol. 2014;28:237–242. doi: 10.1089/end.2013.0325.
    1. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ) Neurourol. Urodyn. 2005;24:215–225. doi: 10.1002/nau.20110.
    1. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology. 2006;68:318–323. doi: 10.1016/j.urology.2006.02.042.
    1. Noblett K, Siegel S, Mangel J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Bennett J, Zylstra S, Kan F. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol. Urodyn. 2016;35:246–251. doi: 10.1002/nau.22707.
    1. Chou EC, Hung MJ, Yen TW, Chuang YC, Meng E, Huang ST, Kuo HC. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment. J. Formos. Med. Assoc. 2014;113:506–512. doi: 10.1016/j.jfma.2012.07.044.
    1. Karstens L, Asquith M, Davin S, Stauffer P, Fair D, Gregory WT, Rosenbaum JT, McWeeney SK, Nardos R. Does the urinary microbiome play a role in urgency urinary incontinence and its severity? Front. Cell Infect. Microbiol. 2016;6:78. doi: 10.3389/fcimb.2016.00078.
    1. Lee UJ, Scott VC, Rashid R, Behniwal A, Wein AJ, Maliski SL, Anger JT. Defining and managing overactive bladder: disagreement among the experts. Urology. 2013;81:257–262. doi: 10.1016/j.urology.2012.09.028.
    1. Karoli R, Bhat S, Fatima J, Priya S. A study of bladder dysfunction in women with type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2014;18:552. doi: 10.4103/2230-8210.137518.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する